External Innovation
We are a global biopharmaceutical company whose mission is to discover, develop and deliver
innovative medicines that help patients prevail over serious diseases.

To accomplish our mission, weare looking into various possibilities, and partnering plays an important strategic role in executing ourR&D strategy, evolving our portfolio and growth. Under this strategy, Bristol Myers Squibb Japan (BMSJapan) actively engage in external innovation activities.
We are actively seeking for partnering opportunities with Japanese academia, research institutes andbiotechs with drug seeds from early to late stages of development.
Furthermore, BMS Japan has a unique collaboration platform to support drug development of academic
seeds of Japan. (Please refer to “Evaluation Process” for more details)

Therapeutic Areas of Focus

SOLID TUMORSHEMATOLOGYCARDIOVASCULARIMMUNOLOGYFIBROTICDISEASESCELL THERAPYRESEARCHTECHNOLOGIESNEUROSCIENCE

Cross-therapeutic Areas of Focus

TRANSLATIONALMEDICINE

DIGITAL HEALTH

For further details, download our Partnering Brochure (EN)Copyright 2021 Bristol Myers Squibb and/or its affiliate/subsidiaryEvaluation Process
1. Application

Please apply via e-mail with the required information (nonconfidential).

2. Primary evaluation

Based on the non-confidential information that we receive, we will
evaluate your research proposal based on the details, novelty, andcollaboration possibility. Please note that the evaluation process willtake approximately 3 weeks.

3. Secondary evaluation

We will arrange a meeting to evaluate the details of the research.
We may ask you to sign a non-disclosure agreement before themeeting, if necessary.

4. Collaboration

We will offer collaboration options based on your research:
Drug development support by BMS Japan:
We will support early-stage research proposals from academia
so that the research can be led to future research collaboration
with BMS Global or in-licensing.

Research collaboration with BMS Global:
Late-stage research proposals from academia and biotech
companies

In-Licensing:
Assets under development by biotech companies

For submission of proposal(s) using Bristol Myers Squibb products, please refer to our BMS US
website: http://www.bms.com
Copyright 2021 Bristol Myers Squibb and/or its affiliate/subsidiary

How to apply
If you would like to send us opportunities for future research collaborations and/or on novel
therapeutic seeds, please contact the Open Innovation Organizing Team via e-mail with the required
information below (non-confidential).
Name



AffiliationHomepage URL (optional)Proposal

Target therapeutic area

Research outline/Non-confidential and disclosable research data to date

Data that can be disclosed after a non-disclosure agreement



Novelty/Superiority of researchIntellectual property

Current alliance status



What role/responsibility is expected for BMS in the proposal

Published articles/literature related to the research (optional)Attachments (optional)

Open Innovation Organizing Team
bms-join@bms.com

Contact
For application or questions on external innovation, please contact the below address:
Open Innovation Organizing Team
bms-join@bms.com

Copyright 2021 Bristol Myers Squibb and/or its affiliate/subsidiary

FAQ
Do I need to apply in English?
Application for primary evaluation may be in Japanese or English, whichever that is preferable, butthere may be cases where we will ask you to prepare English material during the evaluation
process.
How much details should be included in the research outline?
Please describe the outline of your research so that our Open Innovation Organizing Team canadequately understand the details and uniqueness/superiority of your research.
Also, please do not include any confidential data in the application material for primary evaluation
including but not limited to: data of intellectual property that is scheduled for patent application,
data from journals and/or reports that have not been published yet.
Can I apply multiple proposals?
Yes. Please apply each proposal separately.
Can I include confidential information in my research outline?
All proposals are basically evaluated based on non-confidential information.
If you wish to have your proposal evaluated based on confidential data, please contact the Open
Innovation Organizing Team (bms-join@bms.com) before sending any confidential information.
Handling of personal information
All personal information that is sent to Bristol Myers Squibb will be handled properly, and will only
be used for evaluation, registration and administrative purposes of our external innovation
activities. In our evaluation, registration and administrative purposes of our external innovation
activities, there may be cases where personal information will be shared with the Bristol Myers
Squibb Global Headquarters in the United States of America, and its affiliated companies. For otherinformation on handling of personal information, please refer to the Bristol Myers Squibb Japan
privacy policy.
Are there any character limits/file size limits to the research outline?
Please summarize your research outline within 2 pages of A4 size. If you wish to attach
files/materials for reference, please make sure the total file size is within 5MB.
Is there a deadline?
No.

Copyright 2021 Bristol Myers Squibb and/or its affiliate/subsidiaryAppendix: Evaluation Process

Copyright 2021 Bristol Myers Squibb and/or its affiliate/subsidiary